Intelligent Investor

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $3.010 0.21 (7.50%)

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$935 Change of Director's Interest Notice - Thomas 30 Apr 2024 4:04PM $2.800 $3.010 $2.520 risen by 7.50%
$935 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2024 3:37PM $2.790 $3.010 $2.520 risen by 7.89%
$935 Complete response with Cu-67 SAR-bisPSMA 30 Apr 2024 9:37AM $2.560 $3.010 $2.520 risen by 17.58%
$935 Application for quotation of securities - CU6 29 Apr 2024 9:52AM $2.530 $3.010 $2.520 risen by 18.97%
$935 Successful Completion of Retail Entitlement Offer 24 Apr 2024 9:48AM $2.520 $3.010 $2.520 risen by 19.44%
$935 Change in substantial holding 15 Apr 2024 5:01PM $2.650 $3.010 $2.520 risen by 13.58%
$935 Cleaning Notice 15 Apr 2024 10:02AM $2.680 $3.010 $2.520 risen by 12.31%
$935 Application for quotation of securities - CU6 15 Apr 2024 9:58AM $2.700 $3.010 $2.520 risen by 11.48%
$935 Ceasing to be a substantial holder - Taylor 15 Apr 2024 9:26AM $2.700 $3.010 $2.520 risen by 11.48%
$935 Change in substantial holding - Cabbit Pty Ltd 15 Apr 2024 9:23AM $2.700 $3.010 $2.520 risen by 11.48%
$935 Cleansing Notice 8 Apr 2024 9:15AM $2.640 $3.010 $2.520 risen by 14.02%
$935 Application for quotation of securities - CU6 5 Apr 2024 9:47AM $2.690 $3.010 $2.520 risen by 11.90%
$935 Clarity enters into Clinical Supply Agreement 4 Apr 2024 9:47AM $2.740 $3.010 $2.520 risen by 9.85%
$935 Despatch of Retail Entitlement Offer Booklet 4 Apr 2024 9:09AM $2.740 $3.010 $2.520 risen by 9.85%
$935 Completion of Placement and Institutional Entitlement Offer 28 Mar 2024 10:04AM $2.850 $3.010 $2.520 risen by 5.61%
$935 Cleansing Notice 26 Mar 2024 10:29AM $2.850 $3.010 $2.520 risen by 5.61%
$935 Proposed issue of securities - CU6 26 Mar 2024 10:29AM $2.850 $3.010 $2.520 risen by 5.61%
$935 Investor Presentation 26 Mar 2024 10:29AM $2.850 $3.010 $2.520 risen by 5.61%
$935 Clarity launches $121 million equity raise 26 Mar 2024 10:23AM $2.850 $3.010 $2.520 risen by 5.61%
$935 Trading Halt 25 Mar 2024 9:51AM $2.850 $3.010 $2.520 risen by 5.61%
$935 First participant treated in the last dose escalation cohort 22 Mar 2024 9:29AM $2.950 $3.010 $2.520 risen by 2.03%
$935 Change of Director's Interest Notice 21 Mar 2024 9:49AM $3.000 $3.010 $2.520 risen by 0.33%
$935 Cleansing Notice 21 Mar 2024 9:44AM $3.000 $3.010 $2.520 risen by 0.33%
$935 Application for quotation of securities - CU6 21 Mar 2024 9:37AM $3.000 $3.010 $2.520 risen by 0.33%
$935 Theranostic prostate cancer trial advances to multi-dose 15 Mar 2024 10:45AM $2.650 $3.010 $2.520 risen by 13.58%

1 - 25 of 260 results

Page 1 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.